



Australian Technical Advisory Group on Immunisation (ATAGI)

Summary of the 104th meeting, 17 April 2024

Herpes zoster

- ATAGI reviewed and discussed updates to the zoster chapter of the [Australian Immunisation Handbook](#). Public consultation on these changes is expected to take place during June 2024, and the document for consultation will be available on the department's [Consultation Hub](#).

Respiratory syncytial virus (RSV)

- ATAGI reviewed and discussed further changes to the draft RSV chapter, which when finalised will be published in the [Australian Immunisation Handbook](#), expected in late-June 2024.

Influenza

- ATAGI reviewed its advice to the Chief Medical Officer to inform future influenza vaccination programs in Australia.

Pharmaceutical Benefits Advisory Committee (PBAC) advice

- ATAGI received updates from vaccine evaluation groups that are preparing ATAGI advice to the PBAC on vaccines that are being considered for the National Immunisation Program (NIP).

Departmental updates

- ATAGI received an update from the Therapeutic Goods Administration (TGA) on vaccines that are currently under evaluation for registration in Australia.
- ATAGI reviewed a new probity framework. The framework aims to supplement the existing documentation on ATAGI processes by clarifying the process for managing declarations of interest, including the types of relevant interests that should be declared and the categories for managing these declarations.

Resources

- ATAGI's membership, terms of reference and declaration of interest information is available on the [Department of Health and Aged Care website](#).